Quizartinib Dihydrochloride 17.7 mg , 26.5 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 17.7 mg , 26.5 mg

Reference Brands: Vanflyta (USA/EU)

Category: Oncology Cancer Care

Quizartinib Dihydrochloride is a Oncology Cancer Care product available as Tablets in strengths 17.7 mg , 26.5 mg. It corresponds to the reference brand Vanflyta (USA/EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Quizartinib dihydrochloride is a targeted anticancer therapy used in the treatment of acute myeloid leukemia (AML), particularly in patients whose disease carries a mutation in the FMS-like tyrosine kinase 3 (FLT3) gene. AML is a rapidly progressing hematologic malignancy characterized by the uncontrolled growth of immature myeloid cells in the bone marrow and blood. Advances in molecular research have identified several genetic mutations that play a role in the development and progression of AML, with FLT3 mutations being among the most common and clinically significant targets for therapy.

Quizartinib is a second-generation FLT3 inhibitor designed to selectively block the activity of the FLT3 receptor tyrosine kinase. By inhibiting this abnormal signaling pathway, the drug helps reduce the proliferation of leukemia cells and supports better disease control when used as part of combination treatment strategies. Compared to earlier FLT3 inhibitors, quizartinib was developed to provide more targeted and potent inhibition of the FLT3 mutation.

The medicine is available in oral tablet form and is typically used in combination with standard chemotherapy for patients with newly diagnosed FLT3-ITD positive AML, followed by maintenance therapy. Quizartinib represents an important advancement in precision oncology, offering a mutation-directed treatment approach that helps improve outcomes in patients with specific genetic profiles of AML.